BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2.Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of M ...

Key Takeaways CI is up 14.7% YTD, outperforming the industry's 29.1% drop, backed by dual-segment strength. Evernorth revenues rose 16% to $53.7B in Q1 2025; Cigna Healthcare grew 9% year over year. CI faces margin pressure from rising benefit costs and carries $26.5B in long-term debt.The Cigna Group (CI) , a longstanding global health company, continues to offer a variety of health solutions and insurance products. It operates through two main divisions: Cigna Healthcare and Evernorth Health Services. T ...

CVS Health (CVS) and The Cigna Group (CI) stand as two dominant forces in the U.S. diversified healthcare sector, commanding market capitalizations of approximately $77 billion and $84 billion, respectively. Both companies have strategically integrated pharmacy benefit management, insurance coverage and care delivery into comprehensive, consumer-focused platforms designed to address the complexities of modern healthcare.As the industry faces intensifying policy challenges, rapid growth in GLP-1 therapies an ...

Core Viewpoint - UnitedHealth Group has experienced a significant stock decline, with a 5.71% drop on May 21, 2025, bringing its stock price to $302.98, marking a 42% decrease year-to-date and 43% over the last 12 months, primarily due to disappointing Q1 results and reduced full-year guidance [1][9] Peer Comparison - Compared to competitors, UnitedHealth's decline is notable; Cigna increased by 4% in 2025 and 5.8% over the previous year, while Molina Healthcare saw a 2.4% year-to-date increase. Humana, like UnitedHealth, faced a drop of over 45% due to Medicare Advantage pressures [2] Valuation - UnitedHealth is trading at a price-to-sales ratio of 0.7, a price-to-earnings ratio of 12.4, and a price-to-free cash flow ratio of 9.6, all significantly lower than the S&P 500 averages, indicating a potential entry opportunity for long-term investors [3] Growth - The company has shown solid revenue growth, with an average annual growth rate of 11.3% over the last three years and a recent revenue increase of 8.1% from $372 billion to $400 billion [4] Profitability - UnitedHealth's profitability is a concern, with an operating income of $33 billion and a net margin of 5.4%, indicating inefficiencies in converting revenue into profit [5] Financial Stability - The balance sheet remains robust, with $81 billion in debt against a market capitalization of $378 billion, resulting in a moderate debt-to-equity ratio of 29.6% and strong liquidity with $29 billion in cash [6] Downturn Resilience - Historically, UnitedHealth has shown resilience during market downturns, with less severe declines compared to the S&P 500 during crises, indicating its capability to recover from systemic shocks [8] Conclusion - Despite legitimate concerns regarding stock decline and profitability, ongoing revenue growth, a solid balance sheet, and historical resilience suggest that the selloff may be excessive, presenting a compelling recovery narrative for long-term investors [9]

Core Insights - Cigna's pharmacy benefits unit Evernorth has negotiated a deal with drug manufacturers Ely Lilly and Novo Nordisk to reduce the costs of GLP-1 weight loss drugs Wegovy and Zepbound for employers and employees [1][5] Group 1: Cost Reduction and Accessibility - Currently, only half of Cigna's clients cover the GLP-1 weight loss drugs due to high costs, but the new deal aims to make these drugs more accessible [1] - The arrangement allows for a cap on employee out-of-pocket costs at $200 per month, significantly lower than the cash price without insurance [2][3] - Clients already covering weight loss drugs can expect up to a 20% reduction in their costs with the new pricing agreement [5] Group 2: Simplified Processes and Services - The new deal includes a simplified pre-authorization process for accessing the drugs, enhancing convenience for patients [4] - Patients will have access to the drugs at the same price across retail pharmacies and through Evernorth's home delivery service [4] Group 3: Industry Context - CVS Caremark has announced a deal to make Novo's Wegovy its primary weight loss drug, which may affect the preference for Lilly's Zepbound [6] - Eli Lilly is committed to finding solutions to help individuals with obesity access Zepbound, indicating ongoing collaboration within the industry [6]

Core Insights - Evernorth, the health services division of The Cigna Group, has launched a new pharmacy benefit offering that makes weight loss medications WEGOVY® and ZEPBOUND® more accessible to patients, with a maximum monthly cost of $200 [1][6]. Patient Benefits - Patients can save up to $3,600 annually compared to direct-to-consumer manufacturer programs [6][7]. - Monthly copays for GLP-1 weight loss medications will be capped at $200, which will count towards the patient's annual deductible [7]. - The new offering ensures access to FDA-approved medications with robust safety checks to minimize adverse drug interactions [7]. - The prior authorization process will be simplified and automated for quicker access to medications [7]. - Patients have the option to choose from a wide network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy [7]. Employer and Health Plan Sponsor Benefits - Health plan sponsors will experience a significant reduction in the net cost per prescription for GLP-1 medications [7]. - The initiative addresses the growing demand for FDA-approved weight loss medications while ensuring clinical safety for patients [6][7]. - Evernorth's extensive suite of GLP-1 solutions provides health plan sponsors with options to ensure patients have access to the most suitable medications without compromising affordability [7]. Additional Information - EncircleRx has saved health plans $200 million since 2024, with over 9 million enrolled lives [8]. - EnReachRx is a patient support clinical model designed for dispensing GLP-1 prescription medications [8].

Core Points - President Trump signed an executive order aimed at reducing prescription drug prices by up to 90%, targeting pharmaceutical companies and middlemen [1][2] - The order revives the "most favored nation" policy, pushing foreign countries to share more of the R&D costs that the US has been shouldering [2] - The US pays the highest prices for prescription drugs, often nearly three times more than other developed nations [4] Company Impact - Shares of Cigna fell nearly 6% and CVS Health dropped over 3% following the announcement, indicating market concern over the executive order's implications [3][11] - Major US drugmakers initially saw stock declines but later rebounded as analysts suggested the order would be difficult to implement [12] - Merck, Pfizer, Gilead, and Eli Lilly experienced stock increases of 5.9%, 3.6%, 7.1%, and 2.9% respectively, reflecting investor optimism about their resilience against the order [12] Regulatory Actions - The order directs the US Trade Representative and Commerce Secretary to address unreasonable foreign drug pricing policies [6] - Health and Human Services Secretary will set targets for price reductions and initiate negotiations with industry leaders after 30 days [6][7] - The Federal Trade Commission is urged to enhance enforcement against anti-competitive practices by drugmakers [13]

Core Viewpoint - Health insurers, particularly Cigna Group, faced significant stock price declines due to government actions and remarks from President Trump regarding pharmacy benefit managers (PBMs) and drug pricing reforms [1][2][4]. Group 1: Government Actions and Impact - President Trump signed an executive order targeting PBMs, criticizing their role in negotiating drug prices and mandating the pharmaceutical industry to lower drug prices within 30 days [2][4]. - Legislation proposed by the House of Representatives aims to alter PBM compensation structures, with a strong likelihood of passage given Republican control of both the House and Senate [5]. Group 2: Market Reaction - Cigna's stock price dropped by over 5% on a day when the S&P 500 index rose by more than 3.2%, indicating a negative market reaction specifically towards health insurers [1]. - Other healthcare companies with PBMs, such as CVS Healthcare and UnitedHealth Group, also experienced declines in stock prices [6]. Group 3: PBMs Under Scrutiny - PBMs are facing increased criticism for contributing to rising drug prices, making them targets for reform efforts [7]. - Despite potential challenges for Express Scripts, Cigna's overall business is considered robust enough to withstand the impact of a weakened PBM segment [8].

Core Viewpoint - Cigna Group reported strong first-quarter 2025 results with adjusted EPS of $6.74, exceeding estimates by 5.5% and showing a year-over-year increase of 4.2% [1] - Adjusted revenues rose to $65.5 billion from $57.2 billion, beating consensus estimates by 7.7% [1] Financial Performance - The first-quarter results were driven by strong client relationships and growth in Evernorth Health Services, despite rising total benefits and expenses [2] - Cigna's medical customer base decreased by 6% year over year to 18 million, below the consensus estimate of 18.3 million due to the divestiture of Medicare businesses [3] - Total benefits and expenses increased by 16% year over year to $63.5 billion, primarily due to higher pharmacy and medical costs [4] - Adjusted income from operations fell by 2% year over year to $1.8 billion [4] Segment Performance - Evernorth Health Services saw adjusted revenues grow by 16% year over year to $53.7 billion, surpassing estimates of $50.1 billion [5] - Cigna Healthcare segment recorded total revenues of $14.5 billion, a 9% year-over-year increase, exceeding estimates of $12.2 billion [7] - The medical care ratio (MCR) deteriorated by 230 basis points year over year to 82.2% due to increased stop-loss medical costs [8] Financial Position - As of March 31, 2025, Cigna had cash and cash equivalents of $8.3 billion, up from $7.6 billion at the end of 2024 [9] - Total assets decreased to $150.7 billion from $155.9 billion at the end of 2024 [9] - Long-term debt reduced to $26.5 billion from $28.9 billion, while total equity decreased to $40.4 billion from $41.2 billion [9] Cash Flow and Capital Deployment - Cigna generated operating cash flows of $1.9 billion in Q1 2025, a decline of 60.3% from Q1 2024 [10] - The company repurchased shares worth approximately $1.5 billion in the first quarter of 2025, totaling 8.2 million shares for $2.6 billion year to date [12] Outlook - Adjusted EPS for 2025 is now estimated to be at least $29.60, indicating growth of at least 8.3% from 2024 [13] - MCR is projected to be in the range of 83.2-84.2% [13] - Adjusted revenues are forecasted to be a minimum of $252 billion, reflecting an improvement of at least 2% from 2024 [14]

Revenue Growth - Pharmacy revenues increased by 16% to $48,633 million for the three months ended March 31, 2025, compared to $42,036 million in the same period last year[130]. - Total revenues rose by 14% to $65,502 million in Q1 2025, up from $57,255 million in Q1 2024[130]. - Evernorth Health Services revenues increased by 16% to $53,681 million, while Cigna Healthcare revenues rose by 9% to $14,482 million compared to the same period in 2024[1]. - Adjusted revenues for the three months ended March 31, 2025, increased by 16% to $53,681 million, compared to $46,226 million in the same period of 2024[178]. - Pharmacy Benefit Services adjusted revenues increased by 14% to $29,742 million, while Specialty and Care Services revenues grew by 19% to $23,939 million[179]. Net Income and Earnings Per Share - Net income for Q1 2025 was $1,409 million, a significant improvement from a net loss of $212 million in Q1 2024[130]. - Shareholders' net income per share for Q1 2025 was $4.85, compared to a loss of $0.97 per share in Q1 2024[132]. - Shareholders' net income increased by $1,600 million, primarily due to the absence of net investment losses recorded in 2024[3]. Customer Metrics - Medical customers decreased by 6% to 18,043 thousand in Q1 2025, down from 19,184 thousand in Q1 2024[130]. - Medical customers decreased by 6%, mainly due to the HCSC transaction[5]. Operational Performance - Adjusted income from operations for Q1 2025 was $1,840 million, slightly down from $1,875 million in Q1 2024[131]. - The pre-tax margin for the overall operations decreased by 20 basis points to 2.7% from 2.9%[178]. - Pre-tax adjusted income from operations rose by 5% to $1,434 million, up from $1,360 million year-over-year[178]. - The medical care ratio for the Cigna Healthcare segment increased by 230 basis points to 82.2%, reflecting higher medical costs[189]. - The SG&A expense ratio for the Cigna Healthcare segment improved by 110 basis points to 19.4% due to revenue growth outpacing volume-related expenses[189]. - Pre-tax adjusted loss from operations in the Corporate segment remained consistent at $(411) million compared to $(409) million in the prior year[198]. Tax and Costs - The consolidated effective tax rate for Q1 2025 was 14.5%, a significant decrease from 368.4% in Q1 2024[130]. - Integration and transaction-related costs amounted to $216 million in Q1 2025, compared to $37 million in Q1 2024[131]. Investment and Debt - Net investment income decreased by 18% to $238 million in Q1 2025, down from $290 million in Q1 2024[130]. - The debt-to-capitalization ratio was 43.1% as of March 31, 2025, down from 43.8% at the end of 2024[11]. - As of March 31, 2025, the carrying value of the debt securities portfolio decreased from $9.4 billion to $8.2 billion, primarily due to the HCSC transaction[203]. - 84% of the debt securities, amounting to $6.9 billion, were rated investment grade (Baa and above), while $1.3 billion were below investment grade[204]. - The commercial mortgage loan portfolio was valued at $1.3 billion, consisting of approximately 40 fixed-rate loans, with a significant portion of borrower cash invested ranging between 30% and 40%[206]. - Other long-term investments totaled $4.7 billion, including investments in securities limited partnerships and real estate limited partnerships, with no single partnership exceeding 3% of the portfolio[208]. - The unconsolidated subsidiary investments portfolio supporting a joint venture in China was approximately $16.2 billion, with 75% in debt securities[210]. - The majority of the bonds below investment grade were rated at the higher end of the non-investment grade spectrum, consistent with the company's investment strategy[204]. - The commercial mortgage loan portfolio has no exposure to regional shopping malls and less than 25% exposure to office properties[207]. - The company does not expect future declines in investment fair values to have a material unfavorable effect on its financial condition or liquidity[202]. Share Repurchase and Cash Flow - The company repurchased 5.0 million shares for approximately $1.5 billion during the three months ended March 31, 2025[10]. - Operating cash flows decreased to $1,920 million from $4,840 million in the same period last year, primarily due to timing of settlements[9]. Transaction and Acquisitions - The company completed the HCSC transaction on March 19, 2025, with a purchase price of $4.8 billion, receiving $4.2 billion in cash at closing[8]. - Unpaid claims and claim expenses liability decreased by 10% to $4,508 million, driven by the HCSC transaction[193]. - The company expects continued volatility in private equity and real estate fund performance as market valuations adjust[209]. - As of March 31, 2025, there was no material change in the company's risk exposure as reported in the 2024 Form 10-K[213].